Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
NCT05333003
Recruiting
Rates of obesity in patients with schizophrenia-spectrum disorder (SSD)s have reached epidemic proportions, with established contributing effects of antipsychotic (AP) medications. Among agents approved for chronic weight management, glucagon-like peptide-1 receptor agonists (GLP-1RA) are associated with reductions in cardiovascular mortality, with recent FDA approval for once weekly semaglutide for this indication. This study will investigate whether semaglutide is effective in reducing body we... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/04/2024
Locations: Centre for Addiction and Mental Health, Toronto, Ontario
Conditions: Schizophrenia Spectrum Disorders
Register for Updates
A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations
NCT05766709
Completed
Novo Nordisk is developing a combination of 2 medicines (NNC0194-0499 and semaglutide) for the treatment of nonalcoholic steatohepatitis (NASH). NASH is a serious disease where fat, inflammation and scar tissue builds up in the liver. NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used to treat type 2 diabetes and obesity. The study is being done to see how 2 medicines (NNC0194-0499 and semaglutide) are absorbed, transported, and e... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/28/2024
Locations: Altasciences Company Inc., Montreal, Quebec
Conditions: Non-alcoholic Steatohepatitis
Register for Updates
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
NCT04940078
Completed
This study will compare two different ways of giving cagrilintide and semaglutide for treating overweight and obesity. The medicines will either be given together in 1 injection or as 2 separate injections. The aim of the study is to find out how the different ways of injection affect the level of the medicines in the blood. For the first 14 weeks of the study, participants will get cagrilintide and semaglutide as 2 separate injections. Then participants will either switch to getting the medic... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/16/2024
Locations: Altasciences Company Inc., Montreal, Quebec +1 locations
Conditions: Obesity & Overweight
Register for Updates
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
NCT04944992
Completed
The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD. The primary hypotheses are that efinopegdutide is superior to semaglutide, or that efinopegdutide is superior to semaglutide by at least 10% with respect to mean relative reduction from baseline in liver fat content (LFC) after 24 weeks.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/25/2023
Locations: Catalina Research Institute, LLC ( Site 1939), Montclair, California +68 locations
Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Register for Updates
Semaglutide and Vascular Regeneration
NCT05870462
Recruiting
SEMA-VR is a prospective, randomized, 6-month long, open-label study of semaglutide. Approximately 100 participants with type 2 diabetes and/or obesity will be randomized (1:1) to receive semaglutide at escalating doses (up to 1.0 mg/week) or usual care without semaglutide for 6 months. The goal of this trial is to understand how semaglutide exerts cardio-protective effects in people with type 2 diabetes and/or obesity. The main question it aims to answer is: • Does semaglutide treatment prese... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2023
Locations: North York Diagnostic and Cardiac Centre, North York, Ontario +1 locations
Conditions: Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Obesity
Register for Updates
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT03693430
Completed
This study will look at the change in body weight from the start to the end of the study. Researchers will compare the weight loss in people taking semaglutide (a new medicine) to people taking "dummy" medicine. In addition to taking the medicine, participants will also have talks with study staff about healthy food choices, how the participant can be more physically active and what participants can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which treatment... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/05/2023
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +40 locations
Conditions: Overweight, Obesity
Register for Updates
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
NCT03989232
Completed
This study compares the effect of two doses of semaglutide (1.0 mg and 2.0 mg) in people with type 2 diabetes (T2D). People taking part in the study will take the medicine together with their current diabetes medicine (sulphonylurea and/or metformin). Participants will get a dose of either 1.0 mg or 2.0 mg semaglutide once a week - which dose is decided by chance. Participants will inject semaglutide under the skin once a week. The study will last for about 49 weeks. Participants will have 9 cli... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2023
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +128 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Semaglutide vs Sitagliptin
NCT05195944
Unknown
The effect of once daily dosing of oral Semaglutide versus once daily dosing Sitagliptin on glycemic control, body weight, and safety and tolerability will be compared in Liver Transplant Recipients with poorly-controlled Diabetes Mellitus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2022
Locations: Toronto General Hospital, Toronto, Ontario
Conditions: Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis, NAFLD
Register for Updates
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
NCT04153929
Completed
This study is open to adults with type 2 diabetes who take metformin but still have too high blood sugar. The purpose of the study is to find the best dose of BI 456906 that reduces blood sugar. The study also looks at whether BI 456906 helps the participants lose weight. Participants are in the study for about 23 weeks. During this time, most participants visit the study site about 13 times. Some participants visit the study site about 20 times. At the start of the study, the participants are... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/02/2022
Locations: National Research Institute, Huntington Park, California +79 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
NCT02692716
Completed
This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/11/2022
Locations: Novo Nordisk Investigational Site, Little Rock, Arkansas +228 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19
NCT04615871
Unknown
With the results of this study the investigators aim to identify an effective treatment that will reduce morbidity and mortality of patients with symptomatic COVID-19 infection, which would in turn reduce the burden on the healthcare system by decreasing the need for intensive care. Objectives: The main objective of this research is to determine if once weekly treatment with the GLP-1 agonist semaglutide for 4 doses will reduce cardiac as well as non-cardiac complications of COVID-19 infection.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/25/2022
Locations: Instituto Prevent Senior, São Paulo, Not set +9 locations
Conditions: Covid19, Myocardial Injury
Register for Updates
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
NCT03987919
Completed
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2022
Locations: Cahaba Research, Birmingham, Alabama +126 locations
Conditions: Type 2 Diabetes
Register for Updates